We were delighted to participate in the Entrepreneurship Series 2026 organised by the Hong Kong Life Sciences Society (HKLSS), where our Principal, Pauli Wong, delivered a session on "Patent Strategy for Life Sciences Spinouts: From Discovery to Deal-Ready IP". Pauli shared practical insights into the various forms of IP and patent protection available to innovators, key considerations for safeguarding life sciences inventions, and the unique IP opportunities and challenges facing businesses operating across the Greater Bay Area (GBA).

Thank you to HKLSS for the invitation and to all attendees for the engaging discussion. Eagle IP remains committed to supporting innovation, entrepreneurship, and the growth of Hong Kong's life sciences ecosystem.

Our Past Events

Jennifer Che and Pauli Wong Co-Teach Advanced Patent Skills Seminar at HKU-TEC

15 October 2026

BioHK2026 | Biotech IP in practice

16 September 2026

Jennifer Che Once Again Named to the IAM Strategy 300

21 August 2026

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

22 July 2026

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

16 June 2026

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Recommended Insights

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

28 May 2021
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]
Read more >

Is “Comparable” the New “Unexpected”? China’s SPC Relaxes Inventive Step Standard for Breakthrough Therapeutics

14 July 2026
How the Supreme People's Court Established a New Benchmark for Unexpected Technical Effects in a Landmark Diabetic Nephropathy Case Proving inventive step for pharmaceutical compounds, especially a second medical use, remains one of the most challenging aspects of patent prosecution in China. When the prior art discloses a compound's general therapeutic properties, how can an […]
Read more >

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

28 October 2020
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]
Read more >

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
Read more >
Top crossarrow-right